JKB-122
Non‑alcoholic fatty liver disease / Autoimmune hepatitis
Phase 2Active
Key Facts
Indication
Non‑alcoholic fatty liver disease / Autoimmune hepatitis
Phase
Phase 2
Status
Active
Company
About TaiwanJ Pharmaceuticals
TaiwanJ develops small‑molecule drugs for liver and inflammatory diseases using proprietary TLR4/Autotaxin platforms.
View full company profile